New approaches in childhood asthma treatment

Purpose of review This review aims to summarize the most recent advances in asthma management, focusing on novel approaches to pediatric asthma. Recent findings In recent years, the therapeutic tools for pediatric asthma have expanded significantly for both the nonsevere and severe forms. The use of anti-inflammatory treatment, even for the mildest cases, and the withdrawal of symptomatic bronchodilation as monotherapy have been included in the most recent guidelines. Also, different biological therapies have revolutionized the therapeutical approach for severe uncontrolled asthma in children and adolescents. Summary With the expanding landscape of novel therapeutic approaches for pediatric asthma, further evidence is needed to help clinicians choose the best option for patients, particularly those with severe asthma. The identification of novel predictive biomarkers may also help pediatricians in selecting children and adolescents for innovative therapies.

[1]  W. Phipatanakul,et al.  Pediatric asthma and development of atopy 2023. , 2023, Current opinion in allergy and clinical immunology.

[2]  N. Papadopoulos,et al.  Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma. , 2023, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[3]  A. Licari,et al.  Applying the new guidelines to asthma management in children , 2023, Current opinion in allergy and clinical immunology.

[4]  L. Bacharier,et al.  Biologics in the treatment of asthma in children and adolescents. , 2023, The Journal of allergy and clinical immunology.

[5]  L. Bacharier,et al.  Biologics and severe asthma in children , 2022, Current opinion in allergy and clinical immunology.

[6]  Matthew C. Altman,et al.  Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial , 2022, The Lancet.

[7]  E. Novembre,et al.  From the Global Initiative for Asthma report and asthma guidelines to real-life asthma control: is there room for improvement? , 2022, Italian Journal of Pediatrics.

[8]  A. Licari,et al.  Challenges in uncontrolled asthma in pediatrics: important considerations for the clinician , 2022, Expert review of clinical immunology.

[9]  W. Leonard,et al.  Role of thymic stromal lymphopoietin in allergy and beyond , 2022, Nature Reviews Immunology.

[10]  Kevin M. Mendez,et al.  Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma , 2022, Nature Medicine.

[11]  S. Zhai,et al.  Efficacy and Safety of Omalizumab for the Treatment of Severe or Poorly Controlled Allergic Diseases in Children: A Systematic Review and Meta-Analysis , 2022, Frontiers in Pediatrics.

[12]  P. Kuna,et al.  Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. , 2022, The Lancet. Respiratory medicine.

[13]  G. Koppelman,et al.  Biologic Therapies for Severe Asthma. , 2022, The New England journal of medicine.

[14]  A. Licari,et al.  Controversies in the treatment of mild asthma. What novelties and practical implications? , 2022, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[15]  L. Bacharier,et al.  Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. , 2021, The New England journal of medicine.

[16]  Leping Ye,et al.  Pediatric usage of Omalizumab: A promising one , 2021, The World Allergy Organization journal.

[17]  A. Grimes,et al.  The Children's Anti-inflammatory Reliever (CARE) study: a protocol for a randomised controlled trial of budesonide-formoterol as sole reliever therapy in children with mild asthma , 2021, ERJ Open Research.

[18]  C. Brightling,et al.  Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. , 2021, The Lancet. Respiratory medicine.

[19]  C. Porsbjerg,et al.  The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM) , 2021, European Respiratory Journal.

[20]  E. Israel,et al.  Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. , 2021, The New England journal of medicine.

[21]  W. Busse,et al.  Benralizumab for Adolescent Patients with Severe, Eosinophilic Asthma: Safety and Efficacy after Three Years of Treatment. , 2021, The Journal of allergy and clinical immunology.

[22]  G. Canonica,et al.  Allergen immunotherapy: The growing role of observational and randomized trial “Real‐World Evidence” , 2021, Allergy.

[23]  P. O'Byrne,et al.  The management of mild asthma , 2020, European Respiratory Journal.

[24]  A. Licari,et al.  An update on biological therapies for pediatric allergic diseases. , 2020, Minerva pediatrica.

[25]  A. Licari,et al.  Allergen Immunotherapy in Pediatric Asthma: A Pragmatic Point of View , 2020, Children.

[26]  G. Pajno,et al.  Pediatric use of omalizumab for allergic asthma , 2020, Expert opinion on biological therapy.

[27]  A. Licari,et al.  Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents , 2020, Pediatric Drugs.

[28]  A. Licari,et al.  Allergen immunotherapy and asthma , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[29]  T. Hinks,et al.  Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma , 2020 .

[30]  G. Canonica,et al.  Interleukin-5 in the Pathophysiology of Severe Asthma , 2019, Front. Physiol..

[31]  S. Yancey,et al.  Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. , 2019, The Journal of allergy and clinical immunology.

[32]  S. Yancey,et al.  Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma , 2019, Pediatric pulmonology.

[33]  H. Ortega,et al.  Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma , 2019, Allergy, Asthma & Clinical Immunology.

[34]  A. Licari,et al.  Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives , 2019, Pediatric Drugs.

[35]  T. Foiadelli,et al.  Immunomodulation in Pediatric Asthma , 2019, Front. Pediatr..

[36]  A. Sheikh,et al.  GINA 2019: a fundamental change in asthma management , 2019, European Respiratory Journal.

[37]  S. Saglani,et al.  Severe asthma in children: therapeutic considerations , 2019, Current opinion in allergy and clinical immunology.

[38]  S. La Grutta,et al.  The Burden of Pediatric Asthma , 2018, Front. Pediatr..

[39]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[40]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[41]  A. Licari,et al.  New approaches for identifying and testing potential new anti-asthma agents , 2018, Expert opinion on drug discovery.

[42]  Marcus H. Jones,et al.  Impact of omalizumab in children from a middle‐income country with severe therapy‐resistant asthma: A real‐life study , 2017, Pediatric pulmonology.

[43]  J. Corren,et al.  Tezepelumab in Adults with Uncontrolled Asthma , 2017, The New England journal of medicine.

[44]  C. Jenkins,et al.  The paradoxes of asthma management: time for a new approach? , 2017, European Respiratory Journal.

[45]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[46]  A. Licari,et al.  Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience , 2017, Current respiratory medicine reviews.

[47]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[48]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[49]  S. Szefler,et al.  Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. , 2016, The New England journal of medicine.

[50]  H. Neffen,et al.  Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents , 2015, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[51]  I. Pin,et al.  Real-life long-term omalizumab therapy in children with severe allergic asthma , 2015, European Respiratory Journal.

[52]  T. Foiadelli,et al.  Omalizumab in Children , 2014, Pediatric Drugs.

[53]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[54]  K. Rothman,et al.  Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. , 2014, The Journal of allergy and clinical immunology.

[55]  Mike Thomas,et al.  Why asthma still kills: the National Review of Asthma Deaths (NRAD)Confidential Enquiry report , 2014 .

[56]  L. Bacharier,et al.  Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma. , 2014, The Journal of allergy and clinical immunology.

[57]  J. Salleron,et al.  Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey , 2013, European Respiratory Journal.

[58]  E. Naumburg,et al.  Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth. , 2012, The Cochrane database of systematic reviews.

[59]  W. Busse,et al.  Omalizumab and the risk of malignancy: results from a pooled analysis. , 2012, The Journal of allergy and clinical immunology.

[60]  Mark S Levenson,et al.  Age and Risks of FDA-Approved Long-Acting β2-Adrenergic Receptor Agonists , 2011, Pediatrics.

[61]  C. Sorkness,et al.  Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial , 2011, The Lancet.

[62]  Daniel J Jackson,et al.  Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. , 2010, The New England journal of medicine.

[63]  H. Bisgaard,et al.  Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. , 2006, Chest.

[64]  Reynold A Panettieri,et al.  Asthma , 1894, Annals of Internal Medicine.

[65]  K. Schechtman,et al.  A Pragmatic Trial of Symptom-Based Inhaled Corticosteroid Use in African-American Children with Mild Asthma. , 2019, The journal of allergy and clinical immunology. In practice.

[66]  T. Lasserson,et al.  Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events , 2010, Sao Paulo medical journal = Revista paulista de medicina.